Between April 2021 and January 2023, 271 patients (52.0% males) with a mean (SD) age of 61.1 (14.4) years received at least one dose of the Pfizer-BioNTech (BNT162b2) mRNA vaccine.
Of these, 212 patients who had at least one blood sample tested for neutralising antibodies were included in the study. Characteristics of these patients are shown in Table 1. Booster dose was administered on average 26.2 weeks after the second dose. Median interval time between the second and booster doses was 25.4 weeks. There were 34 deaths (16.0%), of which two were related to COVID-19.
Breakthrough infections occurred in 62 (29.3%) patients; 21 (33.9%) and 41 (66.1%) occurred after the second and third doses, respectively, with a median time of 14.3 weeks after the second dose and 16.6 weeks after the third. Overall, a median (IQR) time of 15.5 (13.7, 18.1) weeks elapsed between the last vaccination dose and breakthrough infection. Seven (11.3%) of these patients were convalescent patients. There was no association between history of COVID-19 infection and breakthrough infection (p=0.188).
Table 1. Characteristics of subjects, n = 212
Characteristics
|
|
Mean age, years (SD)
|
59.7 (14.7)
|
Gender
|
|
Male, n (%)
|
112 (52.8)
|
Female, n (%)
|
100 (47.2)
|
Ethnicity
|
|
Malay, n (%)
|
99 (46.7)
|
Chinese, n (%)
|
90 (42.5)
|
Indian, n (%)
|
15 (7.1)
|
Others, n (%)
|
8 (3.8)
|
Total doses of COVID-19 vaccine received
|
|
2 doses, n (%)
|
25 (11.8)
|
2 doses + booster, n (%)
|
187 (88.2)
|
Neutralising antibody response
At some timepoints, the number of samples may be less than the total number of patients as some samples were compromised, volume was too little, or sample was not taken. The number of samples analyzed are stated in the denominator.
Neutralising antibodies against SARS-CoV-2 were detected in 16.8% (n=35/208) ESRD patients at baseline before their first vaccination dose, likely an indication of a recent or prior COVID-19 infection. The median (IQR) nAb titre among these convalescent individuals at baseline were 32.7 BAU/ml (24.6, 72.4) and ranged between 16.1 and 2180 BAU/ml, which was the upper limit of detection.
Neutralising antibodies were detected in 61.9% (n=130/210, median: 95.8 BAU/ml) and 98.4% (n=185/188, median: 2180 BAU/ml) patients after the first and second doses, respectively. The median nAb titres were higher three weeks after the first dose in patients previously exposed to COVID-19 infection (71.6 vs 35.1 BAU/ml) (Figure 2). However, it was not statistically significant (p=0.09). There were also no statistically significant differences in the neutralising antibody reactivity post-first and second doses between convalescent and non-convalescent individuals (Table 2).
Table 2. Neutralising antibody reactivity after doses 1 and 2
|
Prior COVID-19 infection
|
p-value2
|
|
No
|
Yes
|
|
3 weeks post Dose 1
|
|
|
|
Non-reactive
|
70 (39.8%)
|
10 (29.4%)
|
0.255
|
Reactive1
|
106 (60.2%)
|
24 (70.6%)
|
|
1 month post Dose 2
|
|
|
|
Non-reactive
|
1 (0.7%)
|
2 (6.1%)
|
0.08
|
Reactive1
|
154 (99.4%)
|
31 (93.9%)
|
|
1 Reactive (or positive) is determined according to the neutralising antibody index value of ≥ 1.00 U/ml (21.8 BAU/ml)
2 Chi-squared test or Fisher’s Exact test
Median nAb titres reached its peak detectable limit for all vaccinated patients 1 month (mean 4.4 weeks) after the second dose. The median level was reduced to 174.5 BAU/ml by the sixth month (mean 23.5 weeks). However, after the third dose, median nAb levels remained consistently high until the last observed sample 12 months later.
We found younger age to be significantly associated with nAb reactivity at 3 weeks post-first dose (adjusted OR 0.96, 95% CI 0.92, 0.97, p<0.001). The differences were no longer significant after the second dose.